1
Home
Companies

TELA Bio

#9645

Rank

$38.44M

Marketcap

US United States

Country

TELA Bio
Leadership team

Mr. Antony Koblish (Co-founder, Pres, CEO & Director)

Dr. E. Skott Greenhalgh Ph.D. (Chief Technology Officer)

Mr. Peter C. Murphy (Chief Commercial Officer)

Products/ Services
Biotechnology, Life Science, Pharmaceutical
Number of Employees
100 - 500
Headquarters
Malvern, Pennsylvania, United States
Established
2012
Company Registration
SEC CIK number: 0001561921
Revenue
20M - 100M
Traded as
TELA
Social Media
URL
https://www.telabio.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
History

TELA Bio was founded in 2011 with the mission of delivering transformational surgical experience toward improved patient outcomes. The company initially developed a line of implantable medical devices for soft tissue reinforcement and repair. In 2014, TELA Bio expanded its product portfolio with the launch of OviFix™ Surgical Mesh, the first patch specifically designed for transabdominal wall reinforcement, followed by OviTex® Surgical Mesh in 2016. As part of its mission, TELA Bio actively engages in compassionate programs to improve patient care.

Mission
Our mission is to transform the surgical experience with innovative products that improve patient outcomes and quality of life.
Vision
Our vision is to be a leader in tissue repair and transabdominal wall closure and the trusted partner of surgeons and patients around the world.
Key Team

Mr. Roberto E. Cuca J.D. (CFO & COO)

Ms. Megan Smeykal (VP, Corp. Controller, Chief Accounting Officer & Principal Accounting Officer)

Mr. D. Taylor Ocasio (Gen. Counsel)

Mr. Christopher H. Smith (Sr. VP of Sales)

Ms. Jennifer Lou Armstrong (Sr. VP of HR)

Mr. Michael Leonard (Sr. VP of Technical Operations)

Mr. Paul Talmo (Chief Strategic Officer)

Recognition and Awards
TELA Bio has been honored with a number of awards, including the Good Design Award in 2018 and the 2018 Global Health Technologies Coalition Technovation Award.
References

https://in.investing.com/equities/tela-bio-inc

https://finance.yahoo.com/quote/TELA/profile?p=TELA

https://www.crunchbase.com/organization/tela-bio

https://companiesmarketcap.com/

https://www.telabio.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

TELA Bio
Leadership team

Mr. Antony Koblish (Co-founder, Pres, CEO & Director)

Dr. E. Skott Greenhalgh Ph.D. (Chief Technology Officer)

Mr. Peter C. Murphy (Chief Commercial Officer)

Products/ Services
Biotechnology, Life Science, Pharmaceutical
Number of Employees
100 - 500
Headquarters
Malvern, Pennsylvania, United States
Established
2012
Company Registration
SEC CIK number: 0001561921
Revenue
20M - 100M
Traded as
TELA
Social Media
URL
https://www.telabio.com